Preoperative staging of lung cancer with PET/CT: cost-effectiveness evaluation alongside a randomized controlled trial

  • Rikke Søgaard
  • Barbara Malene B. Fischer
  • Jann Mortensen
  • Liselotte Højgaard
  • Ulrik Lassen
Original Article

Abstract

Purpose

Positron emission tomography (PET)/CT has become a widely used technology for preoperative staging of non-small cell lung cancer (NSCLC). Two recent randomized controlled trials (RCT) have established its efficacy over conventional staging, but no studies have assessed its cost-effectiveness. The objective of this study was to assess the cost-effectiveness of PET/CT as an adjunct to conventional workup for preoperative staging of NSCLC.

Methods

The study was conducted alongside an RCT in which 189 patients were allocated to conventional staging (n = 91) or conventional staging + PET/CT (n = 98) and followed for 1 year after which the numbers of futile thoracotomies in each group were monitored. A full health care sector perspective was adapted for costing resource use. The outcome parameter was defined as the number needed to treat (NNT)—here number of PET/CT scans needed—to avoid one futile thoracotomy. All monetary estimates were inflated to 2010 €.

Results

The incremental cost of the PET/CT-based regimen was estimated at 3,927 € [95% confidence interval (CI) −3,331; 10,586] and the NNT at 4.92 (95% CI 3.00; 13.62). These resulted in an average incremental cost-effectiveness ratio of 19,314 €, which would be cost-effective at a probability of 0.90 given a willingness to pay of 50,000 € per avoided futile thoracotomy. When costs of comorbidity-related hospital services were excluded, the PET/CT regimen appeared dominant.

Conclusion

Applying a full health care sector perspective, the cost-effectiveness of PET/CT for staging NSCLC seems to depend on the willingness to pay in order to avoid a futile thoracotomy. However, given that four outliers in terms of extreme comorbidity were all randomized to the PET/CT arm, there is uncertainty about the conclusion. When hospital costs of comorbidity were excluded, the PET/CT regimen was found to be both more accurate and cost saving.

Keywords

PET/CT Cost-effectiveness Lung cancer staging Randomized controlled trial 

Notes

Acknowledgement

The contribution to this study from all of the members in the PERALUST study group is respectfully acknowledged. The following colleagues contributed significantly to this project: S. Larsen from Hvidovre Hospital; A. Loft, AK. Bertelsen, J. Ravn, I. Steffensen and G. Jacobsen from Rigshospitalet, Copenhagen University Hospital, Copenhagen; P. Clementsen, A. Dirksen, P. Vilmann, N. Maltbæk and J. Pedersen from Gentofte Hospital, Copenhagen; A. Hoegholm from Næstved Hospital, Næstved; KR. Larsen, BG. Skov, H. Hansen, V. Backer and H. Nielsen from Bispebjerg Hospital, Copenhagen; TR. Rasmussen, S. Keiding and H. Madsen from Århus Hospital, Århus; O. Gerke, Odense University Hospital, Odense.

This work was funded by a grant from The Danish Cancer Society (application no. R2-A299-B239). Thank you to the John and Birthe Meyer Foundation for providing the PET/CT scanner.

Conflicts of interest

None.

References

  1. 1.
    Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A, et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009;361(1):32–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Maziak DE, Darling GE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, et al. Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med 2009;151:221–8.PubMedGoogle Scholar
  3. 3.
    Scott WJ, Shepherd J, Gambhir SS. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis. Ann Thorac Surg 1998;66(6):1876–83.PubMedCrossRefGoogle Scholar
  4. 4.
    Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach KW, et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med 2000;27(11):1598–609.PubMedCrossRefGoogle Scholar
  5. 5.
    Hayashi K, Abe K, Yano F, Watanabe S, Iwasaki Y, Kosuda S. Should mediastinoscopy actually be incorporated into the FDG PET strategy for patients with non-small cell lung carcinoma? Ann Nucl Med 2005;19(5):393–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Alzahouri K, Lejeune C, Woronoff-Lemsi MC, Arveux P, Guillemin F. Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective. Clin Radiol 2005;60(4):479–92.PubMedCrossRefGoogle Scholar
  7. 7.
    Nguyen VH, Peloquin S, Lacasse Y. Cost-effectiveness of positron emission tomography for the management of potentially operable non-small cell lung cancer in Quebec. Can Respir J 2005;12(1):19–25.PubMedGoogle Scholar
  8. 8.
    Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 1996;37(9):1428–36.PubMedGoogle Scholar
  9. 9.
    Bradbury I, Bonell E, Boynton J, et al. Positron emission tomography (PET) imaging in cancer management. Glasgow: Health Technology Board for Scotland; 2002.Google Scholar
  10. 10.
    The diagnosis and treatment of lung cancer. London: National Institute for Clinical Excellence; 2005.Google Scholar
  11. 11.
    Bird A, Norman R, Goodall S. Economic evaluation of positron emission tomography (PET) in non small cell lung cancer (NSCLC). Sidney: CHERE; 2007.Google Scholar
  12. 12.
    Kosuda S, Ichihara K, Watanabe M, Kobayashi H, Kusano S. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan. Chest 2000;117(2):346–53.PubMedCrossRefGoogle Scholar
  13. 13.
    Verboom P, van Tinteren H, Hoekstra O, Smit E, van den Bergh J, Schreurs A, et al. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Eur J Nucl Med Mol Imaging 2003;30(11):1444–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111(6):1710–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Altman DG. Confidence intervals for the number needed to treat. BMJ 1998;317(7168):1309–12.PubMedGoogle Scholar
  16. 16.
    Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000;19(23):3219–36.PubMedCrossRefGoogle Scholar
  17. 17.
    Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med 2000;19(9):1141–64.PubMedCrossRefGoogle Scholar
  18. 18.
    Buck AK, Herrmann K, Stargardt T, Dechow T, Krause BJ, Schreyögg J. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches. J Nucl Med 2010;51(3):401–12.PubMedCrossRefGoogle Scholar
  19. 19.
    Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ 2002;11(5):415–30.PubMedCrossRefGoogle Scholar
  20. 20.
    Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998;18:S68–80.PubMedCrossRefGoogle Scholar
  21. 21.
    Drummond MF. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.Google Scholar
  22. 22.
    Kristiansen IS, Gyrd-Hansen D. Cost-effectiveness analysis based on the number-needed-to-treat: common sense or non-sense? Health Econ 2004;13(1):9–19.PubMedCrossRefGoogle Scholar
  23. 23.
    Wallace MB, Nietert PJ, Earle C, Krasna MJ, Hawes RH, Hoffman BJ, et al. An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. Ann Thorac Surg 2002;74(4):1026–32.PubMedCrossRefGoogle Scholar
  24. 24.
    Hövels AM, Heesakkers RAM, Adang EMM, Barentsz JO, Jager GJ, Severens JL. Cost-effectiveness of MR lymphography for the detection of lymph node metastases in patients with prostate cancer. Radiology 2009;252(3):729–36.PubMedCrossRefGoogle Scholar
  25. 25.
    Biccard BM, Sear JW, Foëx P. The pharmacoeconomics of peri-operative beta-blocker therapy. Anaesthesia 2006;61(1):4–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Shermock KM, Horn E, Lipsett PA, Pronovost PJ, Dorman T. Number needed to treat and cost of recombinant human erythropoietin to avoid one transfusion-related adverse event in critically ill patients. Crit Care Med 2005;33(3):497–503.PubMedCrossRefGoogle Scholar
  27. 27.
    Buck A, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 2003;44(9):1426–31.PubMedGoogle Scholar
  28. 28.
    Herder GJ, Kramer H, Hoekstra OS, Smit EF, Pruim J, van Tinteren H, et al. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol 2006;24(12):1800–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Vilmann P, Annema J, Clementsen P. Endosonography in bronchopulmonary disease. Best Pract Res Clin Gastroenterol 2009;23(5):711–28.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Rikke Søgaard
    • 1
  • Barbara Malene B. Fischer
    • 2
    • 5
  • Jann Mortensen
    • 2
    • 3
  • Liselotte Højgaard
    • 2
    • 3
  • Ulrik Lassen
    • 4
  1. 1.Centre for Health Service Research and Technology AssessmentUniversity of Southern DenmarkCopenhagenDenmark
  2. 2.Department for Clinical Physiology, Nuclear Medicine and PET, RigshospitaletCopenhagen University HospitalCopenhagenDenmark
  3. 3.Faculty of Health SciencesUniversity of CopenhagenCopenhagenDenmark
  4. 4.Department of Oncology, RigshospitaletCopenhagen University HospitalCopenhagenDenmark
  5. 5.Department of Clinical Physiology and Nuclear MedicineHvidovre HospitalHvidovreDenmark

Personalised recommendations